Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Capricor Therap (NQ: CAPR )

20.41 +0.31 (+1.54%)
Streaming Delayed Price Updated: 9:49 AM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Capricor Therap

< Previous 1 2 3 4 Next >
Why Capricor Therapeutics (CAPR) Shares Are Trading Lower
Capricor Therapeutics shares are trading lower by 2.7% during Thursday's session. The company earlier commenced its public offering of common stock. 
Via Benzinga
CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,800 Today
Via Benzinga
Forecasting The Future: 9 Analyst Projections For Capricor Therapeutics
Via Benzinga
Here's How Much $100 Invested In Capricor Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years
Capricor Therapeutics announced promising 3-year results from its HOPE-2 extension study for deramiocel in treating Duchenne muscular dystrophy, showing significant cardiac and motor function... 
Via Benzinga
Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday
Via Benzinga
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
MarketBeat Week in Review – 9/30 - 10/4
A strong jobs report and a temporary settlement of the port strike lifted stocks but inflation and earnings data could set investors up for more volatility 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Unveiling 6 Analyst Insights On Capricor Therapeutics
Via Benzinga
What's Going On With Capricor Therapeutics Stock Friday?
The biotechnology company said deramiocel increased cardiac function based on several different measures. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Apogee Enterprises Posts Upbeat Earnings, Joins Frontier Group, JetBlue Airways And Other Big Stocks Moving Higher On Friday
Via Benzinga
Nike Reports Weak Sales, Joins Lamb Weston And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
Via Benzinga
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
Via MarketBeat
Exposures Product Safety
Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Down Over 1%; Stitch Fix Shares Plummet
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Nvidia, Alibaba, Capricor Therapeutics, TSMC, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Tuesday, major U.S. indices closed higher, with the Dow Jones Industrial Average gaining 0.2% to reach 42,208.22. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Capricor Therapeutics Stock Is Soaring Tuesday
Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a biologics license application (BLA) for the full approval of Deramiocel for the... 
Via Benzinga
Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and... 
Via Talk Markets
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm
Capricor Therapeutics partners with Nippon Shinyaku for the European commercialization of Duchenne muscular dystrophy treatment, deramiocel, with a potential $1.5 billion in milestone payments from... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.